Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/16/2018 02/19/2018 02/20/2018 02/21/2018 02/22/2018 Date
0.53(c) 0.518(c) 0.51(c) 0.493(c) 0.4965 Last
161 514 168 698 749 160 326 542 1 132 349 Volume
+1.15% -2.26% -1.54% -3.33% +0.71% Change
More quotes
Financials (€)
Sales 2017 3,95 M
EBIT 2017 -10,4 M
Net income 2017 -14,6 M
Finance 2017 17,0 M
Yield 2017 -
Sales 2018 8,00 M
EBIT 2018 -6,53 M
Net income 2018 -8,06 M
Finance 2018 28,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 3,37x
EV / Sales2018 0,26x
Capitalization 30,4 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
Sector
Biotechnology & Medical Research
Calendar
02/28 | 09:30amShareholder meeting
More about the company
Latest news on NEOVACS
07:01aNEOVACS : Strengthens its intellectual property in the usa
GL
02/16NEOVACS : 2018 Financial Calendar
GL
02/14NEOVACS : Announces Positive Data Review from Last IDSMB Review Prior to Final R..
AQ
02/13NEOVACS : Announces Positive Data Review from Last IDSMB Review...
PU
02/13NEOVACS : Announces Positive Data Review from Last IDSMB Review Prior to Final R..
GL
01/16NEOVACS : Strengthened its intellectual property in russia...
PU
01/16NEOVACS : Strengthened its intellectual property in russia
GL
01/16NEOVACS : Strengthened its intellectual property in russia
AQ
2017NEOVACS : Announces positive results of preclinical study for...
PU
2017NEOVACS : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
06:27pSANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
04:22pSangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/13Neovacs : Announces Positive Data Review from Last IDSMB Review Prior to Fina.. 
2017NEOVACS : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR...  
2017Neovacs : ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID.. 
2017Neovacs : announces free allocations of redeemable share...  
2017Neovacs : PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RES.. 
More tweets
Qtime:32
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,62 €
Spread / Average Target 228%
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
Daniel Zagury Director
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS7.17%37
CELLTRION, INC.--.--%34 853
IQVIA HOLDINGS INC2.41%20 749
LONZA GROUP-6.57%19 479
INCYTE CORPORATION-9.71%17 877
NEKTAR THERAPEUTICS39.74%13 613